Assess The Safety Of Pharmaceutical Impurities In Silico

Gain a clearer path to assessing pharmaceutical impurity risk with advanced in silico modeling designed to support ICH M7 (R2) compliance. By combining knowledge-based structural analysis with probability-driven predictions, this approach delivers insight into genotoxicity, carcinogenicity, and broader toxicity endpoints without overreliance on in vitro testing. Detailed outputs not only classify compounds but explain the “why” behind each result, offering mechanisms of action, statistical confidence, and comparisons to similar structures backed by experimental data. These insights strengthen expert review and help build defensible regulatory submissions while identifying acceptable exposure levels.

For teams navigating complex impurity profiles, see how to enable faster, cost-effective, and more confident decision-making grounded in transparent, evidence-based predictions.